2025年 新着論文 38 細胞情報学分野から論文が発表されました

hnRNPL-CstF64 complex: coordinating CSR and LSR in IgH locus recombination dynamics through eRNA and NHEJ regulation

Nucleic Acids Res. 2025 Aug 27;53(16):gkaf810. doi: 10.1093/nar/gkaf810.

Authors

Farazul Haque  1 Mikiyo Nakata  1 Hidetaka Kosako  2 Tasuku Honjo  1 Nasim A Begum  1

Affiliations

  • 1 Department of Immunology and Genomic Medicine, Centre for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan.
  • 2 Division of Cell Signaling, Institute of Advanced Medical Sciences, Tokushima University, Tokushima 770-8503, Japan.

Abstract

Class switch recombination (CSR) and locus suicide recombination (LSR) are critical processes involved in the immune system’s ability to diversify antibody responses. Both are initiated by activation-induced cytidine deaminase, which induces DNA double-strand breaks (DSBs) at specific regions within the immunoglobulin heavy chain (IgH) locus. In CSR, DSBs occur at the switch (S) regions, allowing B cells to replace the IgM heavy chain constant region (CH) with other isotypes, thereby enhancing immune adaptability. This process is regulated by both cis and trans mechanisms, including the IgH super-enhancer 3′ regulatory region (3’RR) and the production of enhancer RNAs (eRNAs). A recent study highlighted the role of MED12 in CSR through enhancer activation and the transcription of eRNA. Now, we show that heterogeneous ribonucleoprotein L (hnRNPL) acts as an additional regulator of CSR and LSR by forming an eRNA-associated complex with CstF64, a polyadenylation factor. This complex facilitates RNA polymerase II elongation and eRNA transcription at the 3’RR. Moreover, the hnRNPL/CstF64 complex promotes NHEJ-mediated DNA repair at both S and 3’RR regions, facilitating 53BP1 and Ku80 recruitment, thereby impacting the efficiency of CSR and LSR. This discovery highlights the intricate, multimodal regulation of these processes, linking eRNA transcription to DNA repair in the process of antibody diversification.

Conflict of interest statement

None declared.

Full text links